Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary findings after multi-gene panel testing in 7,388 patients with suspected cancer predisposition syndrome.

Scientific reports - 10 Apr 2026

Avsec Eva, Blatnik Ana, Šetrajčič Dragoš Vita, Škerl Petra, Stegel Vida, Krajc Mateja

Abstract excerpt

Our study focused on the individuals’ preference for disclosure of secondary findings (SF) in hereditary cancer genes (HCG) and the frequency and type of SF after multi-gene panel testing (MGPT) in individuals with a suspected cancer predisposition syndrome (CPS). SF are defined as pathogenic/likely pathogenic variants (P/LPV) that were not anticipated and without a known correlation to the primary indication for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Neoplastic Syndromes, Hereditary

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 41957288
DOI: 10.1038/s41598-026-48598-w
PMCID: PMC13199422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary findings after multi-gene panel testing in 7,388 patients with suspected cancer predisposition syndrome.PMID 41957288Read ↗

Changes in multi-gene cancer panels for children: A 4-year retrospective review.Semantic proximity Read ↗

Reporting Practices for Secondary Findings among ERN GENTURIS Member Institutions in 15 European CountriesSemantic proximity Read ↗

Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.Semantic proximity Read ↗

Current Indications for Consideration of Evaluation for Hereditary Cancer Predisposition Syndromes and How They Can Change Management.Semantic proximity Read ↗

Risks and Implications of Multiple Actionable Pathogenic Germline Variants Discovered by Panel-Based Cancer Predisposition Testing.Semantic proximity Read ↗

An analysis of the impact of annual cancer genetic testing guideline updates on a past patient population.Semantic proximity Read ↗

ACMG Secondary Findings in the Brazilian Rare Genomes Project: Insights from 5,402 genome sequencingSemantic proximity Read ↗

Reporting framework in the testing of predisposition to common adult solid tumors using next-generation sequencing.Semantic proximity Read ↗

A comprehensive genomic reporting structure for communicating all clinically significant primary and secondary findingsSemantic proximity Read ↗

Consideration for Multigene Panel Testing Outside of Cancer-Specific Genetic Testing.Semantic proximity Read ↗

Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.Semantic proximity Read ↗

Update on Genetic Counselor Practice and Recommendations for Pediatric Cancer Predisposition Evaluation and Surveillance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.